Ribavirin-Free Regimen with Sofosbuvir and Velpatasvir Is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients with Genotypes 2 and 3 Chronic Hepatitis C: Results from Astral-2 and -3 Clinical Trials

Clinical Infectious Diseases

Volumn 63, Issue 8, 2016, Pages 1042-1048

  Younossi, Zobair M ^a   Stepanova, Maria ^b   Sulkowski, Mark ^c   Foster, Graham R ^d   Reau, Nancy ^e   Mangia, Alessandra ^f   Patel, Keyur ^g   Bräu, Norbert ^h   Roberts, Stuart K ⁱ   Afdhal, Nezam ^j   Nader, Fatema ^b   Henry, Linda ^b   Hunt, Sharon ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

Direct acting antivirals; Fatigue; Health related quality of life; Hepatitis C; Work productivity

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN PLUS SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE HCV; DRUG EFFICACY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MOOD DISORDER; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK PRODUCTIVITY ACTIVITY INDEX:SPECIFIC HEALTH HEALTH PROBLEM; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMORBIDITY; GENETICS; GENOTYPE; HEPACIVIRUS; MULTICENTER STUDY; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; VIROLOGY; VIRUS LOAD;

ADULT; CARBAMATES; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84990989646     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw496     Document Type: Article

References (45)

1. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
3. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
4. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
5. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
6. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359-65. (PEARL II).
7. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82. (TURQUOISE II).
8. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-14. (SAPPHIRE II).
9. Smith MA, Regal RE, Mohammad RA. Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother 2016; 50:39-46.
10. Nelson DR, Cooper JN, Lalezari JP, et al. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-35.
11. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-65.
12. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
13. Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 2014; 7:555-66.
14. Cheetham TC, Niu F, Chiang K, et al. Factors associated with failure to achieve SVR in hepatitis C genotype 3 patients within an integrated care delivery system. J Manag Care Spec Pharm 2015; 21:641-7.
15. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42:559-73.
16. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63:337-45.
17. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41:497-520.
18. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015; 212:367-77.
19. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46(suppl 5):S186-96.
20. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59:2161-9.
21. Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013; 38:124-33.
22. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014; 60:741-7.
23. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12:1349-59.e13.
24. Gerber L, Estep M, Stepanova M, Escheik C,Weinstein A, Younossi ZM. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016; 14:156-64.e3.
25. Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 2016; 36:42-8.
26. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology 2015; 61:1798-808.
27. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61:228-34.
28. Younossi Z, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 2016; 111:808-16.
29. Aggarwal J, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z, Goss TF. Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. J Viral Hepat 2015; 22:8-17.
30. Younossi Z, Stepanova M, Nader F, Henry L. Patient-reported outcomes in elderly patients with chronic hepatitis C treated with interferon-and ribavirin-free regimens. J Am Geriatr Soc 2016; 64:386-93.
31. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon-and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015; 42:286-95.
32. Baran RW, Samp JC, Walker DR, et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ 2015; 18:691-703.
33. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patientreported outcomes in HCV patients: results from Astral-1 placebo-controlled trial. J Hepatol 2016; 65:33-9.
34. Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised openlabel ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 2016; doi:10.1016/ S2468-1253(16)30020-6.
35. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10:405-13.
36. Webster K, Odom L, Peterman A, Lent L, Cella D. The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999; 8:604.
37. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45:295-300.
38. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics 1993; 4:353-65.
39. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012; 19(suppl 1):42-7.
40. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51:655-66.
41. Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20:15233-40.
42. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790-800.
43. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 1:4.
44. Teuber G, Schäfer A, Rimpel J, et al. Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol 2008; 49:923-9.
45. Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016; 23:217-26.